Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study
Japanese Journal of Clinical Oncology · 03.08.2025 · 55 (8) · 954-962
DOI: 10.1093/jjco/hyaf079 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 18.05.2025. Verfasst von Yosuke Kinoshita und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba University Graduate School of Medicine, 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670, Japan. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists, Prostatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: KAKENHI, Yasuda Medical Foundation, Naito Foundation.
Abstract (Originalsprache)
Background
This study investigated clinical benefits of androgen receptor signaling inhibitor (ARSI) in patients with synchronous metastatic hormone-sensitive prostate cancer (mHSPC) based on real-world data from multiple centers.
Methods
Clinical records of 1107 mHSPC patients who commenced vintage (bicalutamide) (n = 801) or ARSI (n = 306) treatment in addition to androgen deprivation therapy between 1999 and 2024 were reviewed. Progression-free and overall survival (OS) were examined, and prognostic factors were analyzed using multivariate cox proportional hazard modeling. Propensity score matching (PSM) analysis was performed to balance background characteristics.
Results
Median age and initial prostate-specific antigen level were 73 years and 229 ng/ml, respectively. Kaplan–Meier analysis revealed that upfront ARSI treatment was associated with longer progression-free survival (P < 0.0001, hazard ratio [HR] = 0.37) and OS (P = 0.0088, HR = 0.58) than combined androgen blockade after PSM analysis. In particular, an OS benefit of upfront ARSI was observed in high-volume patients (P = 0.0052, HR = 0.56). ARSI use after castration-resistant prostate cancer (CRPC) development correlated with improved OS as compared to patients without ARSI use (P < 0.0001, HR = 0.52). Multivariate analysis identified ARSI therapy as an independent prognostic factor for OS both when used upfront (P = 0.0141, HR = 0.61) and after CRPC development (P < 0.0001, HR = 0.55). In addition, categorizing all patients into groups receiving no ARSI, ARSI after CRPC, or ARSI as upfront therapy revealed 5-year OS rates of 55.65%, 59.85%, and 65.01%, respectively.
Conclusions
Early use of ARSI in Japanese patients with mHSPC appears clinically beneficial. Our findings suggest the prognostic importance for optimal treatment intensification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Chiba University Graduate School of Medicine, 1.8.1, Inohana, Chuo.ku, Chiba.City, Chiba 2608670, Japan.
- Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki-City, Osaka 5698686, Japan.
- Department of Urology, Kimitsu Chuo Hospital, 1010, Sakurai, Kisarazu-City, Chiba 2928535, Japan.
- Department of Urology, Chiba Rosai Hospital, 2-16, Tatsumidaihigashi, Ichihara-City, Chiba 2900003, Japan.
- Department of Urology, Chibaken Saiseikai Narashino Hospital, 1-1-1, Izumi, Narashino-City, Chiba 2758580, Japan.
- Department of Urology, Funabashi Municipal Hospital, 1-21-1, Kanasugi, Funabashi-City, Chiba 2738588, Japan.
Förderung
- KAKENHI
- Yasuda Medical Foundation
- Naito Foundation
Zitieren
APA
Kinoshita, Y., Yamada, Y., Tsujino, T., Xue, Z., Sato, K., Saito, S., Nishimura, K., Fukushima, T., Nakamura, K., Yamamoto, S., Arai, T., Sato, H., Higuchi, K., Takei, A., Kanesaka, M., Ando, K., Pae, S., Kanaoka, S., Takeshita, N., …, & Sakamoto, S. (2025). Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study. Japanese Journal of Clinical Oncology, 55(8), 954-962. https://doi.org/10.1093/jjco/hyaf079
Vancouver
Kinoshita Y, Yamada Y, Tsujino T, Xue Z, Sato K, Saito S, et al. Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study. Japanese Journal of Clinical Oncology. 2025;55(8):954-962. doi:10.1093/jjco/hyaf079
BibTeX
@article{Kinoshita2025,
author = {Kinoshita, Yosuke and Yamada, Yasutaka and Tsujino, Takuya and Xue, Zhao and Sato, Kodai and Saito, Sinpei and Nishimura, Kazuki and Fukushima, Tatsuo and Nakamura, Ko and Yamamoto, Satoshi and Arai, Takayuki and Sato, Hiroaki and Higuchi, Kosuke and Takei, Akinori and Kanesaka, Manato and Ando, Keisuke and Pae, Sangjon and Kanaoka, Sanji and Takeshita, Nobushige and Yoneda, Kei and Hino, Daichi and Sazuka, Tomokazu and Imamura, Yusuke and Mikami, Kazuo and Nakamura, Kazuyoshi and Fukasawa, Satoshi and Kurozumi, Akira and Naya, Yukio and Nagata, Maki and Komaru, Atsushi and Tobe, Toyofusa and Suzuki, Noriyuki and Azuma, Haruhito and Ichikawa, Tomohiko and Sakamoto, Shinichi},
title = {Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
volume = {55},
number = {8},
pages = {954--962},
doi = {10.1093/jjco/hyaf079}
}
EUVIMED